Answers are grounded in this paper and cite their sources.
Senescence is an anti-tumour mechanism and hallmark of cancer. Loss or mutation of key senescence effectors, such as p16INK4A, are frequently observed in cancer. Intriguingly, some human tumours are both proliferative and senescent-marker positive (Sen-Mark+). Here, we explore this paradox, focusing on the prognostic consequences and the current challenges in classifying these cells. We discuss future strategies for Sen-Mark+ cell detection together with emerging opportunities to exploit senescence for cancer.
No takes yet. Share an insight, caveat, or question.
O'Sullivan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: